Compare Medpace Holdings Inc (MEDP) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Msci Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Msci Inc trades at $565.48 (market cap $40.38B). The key difference: Msci Inc is far larger — about 2.4× Medpace Holdings Inc's market cap, and Msci Inc pays a 1.48% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Msci Inc for 82 Days on average.
| MEDP | MSCI | |
|---|---|---|
Market Cap | $16.82B | $40.38B |
Volume | 223,093 | 414,140 |
Sector | Health | Financials |
52-Week High | $630.19 | $643.83 |
52-Week Low | $393.42 | $511.84 |
Typical Hold Time | 14 Days | 82 Days |
Enterprise Value | $16.44B | $46.54B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
MSCI trades at $565.12, up 1.75% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $3.13B, net income of $1.20B, and high margins. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 slightly missed. The company maintains strong cash flow and completed the acquisition of First Street in August 2026, enhancing its climate risk analytics offerings.
Outlook remains positive with a consensus price target of $701.71, implying significant upside. Key opportunities include recurring revenue growth and expansion in private markets. Risks include high valuation multiples, debt levels, and market sensitivity to financial services demand. Investors should weigh strong profitability against premium pricing and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
